Drug use in the United States remains a complex and pervasive issue, requiring a comprehensive and

multifaceted approach. One key avenue for addressing this challenge is through the efforts of the

federal government’s Office of Drug Control Policy.

The Federal Drug Control Budget has seen significant increases over time. In 2000, the budget stood at

$17.9 billion. By 2015, it had risen to $26 billion, and for 2024, it climbed even further to $43.6 billion.

Despite these increased investments, the ongoing struggles with drug use, abuse, and addiction raise an

important question: Are we allocating these funds in the most effective way?

To gain insight into this, it’s essential to examine where the money has been directed. In 2015, 56% of

the budget focused on Supply Reduction—including interdiction, eradication, and law enforcement

efforts. The remaining 44% was spent on Demand Reduction—such as education, prevention, and

treatment initiatives.

Both areas are crucial to combating the drug epidemic. Reducing supply, by making drugs more

expensive and harder to access, can indirectly lower demand. However, this approach faces challenges,

as the nature of the drug supply continuously evolves. Advances in technology have led to rapid

changes in the types of drugs consumed and the methods by which they are obtained, creating a moving

target for policymakers. This dynamic underscores the complexity of crafting impactful strategies to

address drug use in the United States.

Reducing the Demand for Drugs: A Critical Component of the Solution

The demand for drugs represents a pivotal side of the equation in addressing the drug crisis. By

reducing the number of individuals seeking drugs, the supply becomes less consequential. Over the past

nine years, the federal government has increasingly recognized the importance of demand reduction.

This shift is reflected in the 2024 budget, where 55.6% of the funds are allocated to Demand

Reduction—encompassing education, prevention, and treatment—while 44.4% is directed toward

Supply Reduction, such as interdiction and law enforcement.

Despite this reallocation of resources, the United States continues to grapple with widespread drug use.

A deeper examination reveals a key issue: the disparity in spending between treatment and prevention,

and the varying outcomes each achieves.

Funding for treatment is undoubtedly critical, as it provides essential support for individuals battling

substance use disorders. However, access to quality treatment remains a significant barrier. Many

individuals face challenges such as the high cost of care and the difficulty of maintaining employmentwhile undergoing treatment. For instance, the most effective treatment for opioid addiction is a 3–6

month residential program. Yet, these programs are financially burdensome and still have an alarmingly

high relapse rate of 80%. While treatment addresses existing demand, its impact is limited and does

little to prevent future drug use.

Prevention, on the other hand, targets future demand by focusing on younger populations, particularly

teenagers who are most at risk of becoming future users. Despite its critical role, prevention efforts

receive just 6.3% of the overall budget, in stark contrast to the 49.3% allocated for treatment. Investing

in effective prevention programs has the potential to significantly reduce future demand, making it a

vital yet underfunded aspect of the overall strategy.

It is essential to consider the cost-benefit dynamics of prevention programs. Although assigning a

monetary value to saving a life or relieving a family from the challenges of a loved one’s struggle with

substance use is complex, the National Institute on Drug Abuse highlighted one program that

demonstrates the positive potential. They calculated a return of $12.88 for every dollar invested in the

initiative. This demonstrates that well-designed prevention programs are not only a wise investment in

the well-being of individuals but also in the resilience and prosperity of the community as a whole.

The continued struggles with drug use in the United States highlight the need to strike a more balanced

approach. By prioritizing prevention (increasing the percentage of the Drug Control Budget that is

spent on prevention) alongside treatment, the nation can address not only the current challenges but

also lay the groundwork for a healthier, safer, and more productive future.

References

The Federal Drug Control Budget figures for 2000, 2015, and 2024, as well as the allocation

percentages for Supply Reduction and Demand Reduction in 2015, are discussed in the National Drug

Control Budget: FY 2024 Funding Highlights.

Additional insights into the budget allocations and strategies can be found in the Budget and

Performance section of the Office of National Drug Control Policy.

The challenges of accessing quality treatment, including financial burdens and employment difficulties,

are discussed in the American Addiction Centers’ guide on rehab success rates and statistics.

The effectiveness of 3–6 month residential programs for opioid addiction and the high relapse rate of

80% are highlighted in the Addiction Group’s report on relapse rates and statistics.

National Institute on Drug Abuse. (2022, April 28). Investing in prevention makes good financial sense.

From the website National Institute on Drug Abuse.

Vertex Pharmaceuticals has received FDA approval for its new pain medication, Journavx, designed to offer a non-addictive alternative to traditional opioids. Intended for short-term pain relief following surgeries or injuries, Journavx aims to address the growing concerns over opioid addiction and overdose risks.

A Non-Opioid Alternative

Unlike opioids such as Vicodin or OxyContin, Journavx offers a novel approach to pain management. It targets pain without the addictive properties or overdose risks associated with opioids, making it a potential game-changer for those seeking pain relief without the dangers of traditional medications.

A Groundbreaking Approach to Pain Relief

Journavx represents the first new pharmaceutical approach to pain management in over two decades. It stands as a promising alternative to both opioids and over-the-counter pain relievers, offering patients a fresh option in the battle against pain while avoiding the risks associated with more commonly used medications.

Effectiveness

In clinical studies involving over 870 patients, Journavx was shown to provide more pain relief than a placebo. However, it did not surpass the effectiveness of the commonly used opioid-acetaminophen combination pill. Despite this, its ability to offer relief without the addictive side effects of opioids positions it as a valuable addition to the pain management landscape.

Mechanism of Action

Journavx works by blocking specific proteins that trigger pain signals before they even reach the brain, distinguishing it from opioids, which bind to brain receptors to alleviate pain. This mechanism helps reduce the risk of addiction and overdose, marking a significant departure from traditional painkillers.

Cost Considerations

At $15.50 per pill, Journavx is considerably more expensive than generic opioids, which can cost as little as $1 or less. While its higher price point may be a concern for some, the drug’s non-addictive properties and reduced risk of overdose could make it a valuable option for those in need of short-term pain relief.

Development and Context

Vertex Pharmaceuticals began researching Journavx in the early 2000s, during a time when opioid overprescription was at its peak. The inspiration behind the drug came from studying a rare genetic condition that causes insensitivity to pain, providing the foundation for a new approach to pain management. While the opioid crisis is now largely driven by illicit fentanyl, this new medication offers a promising path forward for addressing the crisis in prescription painkillers.

Side Effects and Future Research

Like most medications, Journavx has potential side effects, with the most common being nausea, constipation, itching, rash, and headaches. Vertex Pharmaceuticals plans to continue research into the use of this drug for chronic pain, despite some disappointing test results in this area. Further studies are expected to explore the potential for Journavx in treating long-term pain conditions.

Journavx is based on research inspired by individuals with a rare genetic condition that causes them to be insensitive to pain, providing hope that it could help a broader patient population in the future.

https://apnews.com/article/nonopioid-painkiller-fda-vertex-pharmaceuticals-b1dd4276fce3d88ff32e3062e95f408f

A recent report from the Commonwealth Fund highlights a grim reality: the United States leads the world in drug overdose deaths, significantly outpacing other nations. Despite slight progress in 2023, the country continues to grapple with a devastating crisis fueled by synthetic opioids like fentanyl.

A Worsening Trend

While overdose deaths in the U.S. dipped slightly around 2018, they began to rise again in 2019 and surged during the COVID-19 pandemic. In 2023, the numbers decreased by 3%, but more than 100,000 people still lost their lives to overdoses.

Staggering Numbers

In 2022, the U.S. had the highest rate of overdose deaths among 30 countries and one territory, with 324 deaths per 1 million residents. Other heavily impacted areas included:

• Puerto Rico: 246 deaths per 1 million
• Scotland: 219 deaths per 1 million
• Canada: 193 deaths per 1 million

Key Contributing Factors

Several factors set the U.S. apart from other nations in terms of overdose deaths:

• Limited Harm Reduction Measures: Many countries provide broad access to naloxone (an overdose reversal drug) and supervised drug consumption sites—measures that remain limited in the U.S.
• Fentanyl’s Deadly Grip: This synthetic opioid is 50 times stronger than heroin and was involved in over 84,000 overdose deaths in the U.S.
• Emerging Synthetic Opioids: New synthetic opioids, such as nitazenes, are becoming more common in Europe and Brazil, signaling a growing international crisis.
• Policy Gaps and State Differences: The U.S. lacks a unified national strategy, with states enforcing widely varying policies on drug treatment and harm reduction.

A Call for Action

While the slight decline in overdose deaths in 2023 provides a glimmer of hope, the overall numbers remain alarmingly high. Addressing the crisis requires a coordinated approach that includes expanding harm reduction measures, improving access to treatment, and tackling the growing presence of synthetic opioids. Without significant action, the U.S. will likely continue to lead the world in this preventable tragedy.

https://thehill.com/policy/healthcare/5078221-us-highest-overdose-deaths

Nicotine pouches, such as Zyn, O!, Rogue, Juice Head, and VELO, are small, flavored pouches containing nicotine or synthetic nicotine. Users place them between their lip and gum, where the nicotine is absorbed directly into the bloodstream. These smokeless products have surged in popularity, especially among young people, raising concerns for parents, schools, and health experts.

Who Are They Really For?

• Intended Audience: Legally marketed to adults 21+ as an alternative to smoking or vaping.
• Actual Audience: Rapidly growing in popularity among teenagers and young adults, despite age restrictions.

Why Are Nicotine Pouches So Popular Among Youth?

• Easily Accessible – Available at gas stations, convenience stores, and online. Many minors can purchase them without strict ID checks.
• Hidden in Plain Sight – Unlike vaping or smoking, nicotine pouches are smokeless and odorless, making them easy to use in school without detection.
• Social Media Promotion – “Zynfluencers” on platforms like TikTok normalize and promote their use, increasing exposure to youth.
• Athlete Endorsements – Professional athletes have been seen using and promoting these products.

Alarming Sales and Usage Trends

• In Q1 of 2024, Zyn alone sold 131.6 million cans worldwide, an 8.2% increase from the previous year. Sales are projected to reach 560 million cans by the end of 2024.
• A CDC report found that 1.8% of middle and high school students (about 890,000 youth) use nicotine pouches—an increase from 1.5% in 2023.
• The American Lung Association estimates that 25% of nicotine pouch users are underage.

Health Concerns: More Than Just Nicotine Addiction

How Much Nicotine Are Kids Really Consuming?

• A 6mg nicotine pouch delivers as much nicotine as 3 packs of cigarettes or 1.5 vape pods (2% strength) per day.
• Many young users chain-use multiple pouches, dramatically increasing their nicotine intake.

Known Health Risks

• Nicotine addiction – Even low doses can quickly lead to dependence, especially in developing brains.
• Cognitive Impairment – Nicotine affects attention, memory, and learning, making it harder for students to focus in school.
• Nicotine Poisoning – High doses can cause nausea, vomiting, dizziness, and increased heart rate.
• Long-Term Health Risks – Nicotine use is linked to cardiovascular problems, increased cancer risk, and respiratory issues.
• Chemical Exposure – A 2022 study found 26 nicotine pouch samples contained cancer-causing chemicals, including ammonia, chromium, formaldehyde, nickel, and nicotine salt.

How Are Companies Getting Away With This?

• Big Tobacco Ties – Zyn is owned by Swedish Match, which is controlled by Philip Morris (the makers of Marlboro Cigarettes, Veev Vapes, and a 35% owner of JUUL Vapes).
• Marketing Loopholes – While Zyn denies using influencers, nicotine pouches are frequently promoted online, increasing exposure to minors.
• Regulatory Challenges – The FDA has issued warnings to retailers selling to minors, and some states are banning flavored nicotine products, but companies often find ways around restrictions.

What Can Be Done?

• More Research & Regulation – Health experts are calling for stricter enforcement of age restrictions and more research into the long-term effects of nicotine pouches.
• School Prevention Programs – Many schools are now implementing specialized prevention curriculums to educate students about the dangers of nicotine pouches.
• Parental Awareness – Parents need to be aware that their child could be consuming the equivalent of 3 packs of cigarettes a day without them knowing. Conversations about the dangers of nicotine addiction should start early.

Final Thought: A Growing Epidemic

While nicotine pouches may seem less harmful than traditional cigarettes, their high nicotine content, addictive nature, and appeal to youth make them a significant public health concern. Without stronger prevention efforts, more young people will become addicted to nicotine, putting their long-term health at serious risk.

https://www.cnn.com/2024/12/30/health/zyn-young-users

https://www.lung.org/blog/zyn-nicotine-addiction

A recent study from McGill University suggests that cannabis use can heighten vulnerability to psychosis by disrupting synaptic density in the brain. This disruption weakens nerve cell connections, particularly affecting young adults already at risk of developing psychotic disorders. As a result, symptoms may worsen, potentially contributing to the onset of more severe mental health conditions.

Key Research Findings

Researchers at McGill University observed a significant decrease in synaptic density among individuals at risk of psychosis compared to a healthy control group. These findings highlight how cannabis impacts brain connectivity, reinforcing concerns about its potential role in worsening psychiatric symptoms.

“Not every cannabis user will develop psychosis, but for some, the risks are high,” noted Dr. Romina Mizrahi, one of the study’s leading researchers.

Impact on Brain Development

The study underscores how cannabis interferes with the brain’s natural process of refining and pruning synapses—a crucial function for healthy cognitive and emotional development. Disrupting this process may lead to long-term consequences, particularly for young individuals whose brains are still maturing.

Study Participants and Methodology

The study involved 49 participants between the ages of 16 and 30, including individuals with recent psychotic symptoms and those classified as high-risk for developing psychosis. The research team found that lower synaptic density was associated with symptoms such as social withdrawal and lack of motivation—challenges that remain difficult to treat with current medications.

Next Steps in Research

The next phase of this study will examine whether these cannabis-related brain changes can serve as early indicators of psychosis, potentially paving the way for earlier intervention and improved treatment strategies.

Institutional Support

This research was conducted at the Douglas Mental Health University Institute and McGill University’s Montreal Neurological Institute-Hospital, with funding from the Canadian Institute of Health Research.

As the conversation around cannabis use and mental health continues, this study adds to the growing body of evidence suggesting that cannabis may have significant effects on brain function, particularly for individuals vulnerable to psychotic disorders.

https://www.mcgill.ca/newsroom/channels/news/cannabis-disrupts-brain-activity-young-adults-prone-psychosis-study-361318#:~:text=Cannabis%20disrupts%20brain%20activity%20in%20young%20adults%20prone%20to%20psychosis%3A%20study,-McGill%20research%20findings&text=Young%20adults%20at%20risk%20of,symptoms%20that%20current%20medications%20miss.

Risks of Misuse:

• Health Hazards: Inhaling pure nitrous oxide can lead to:
  • Loss of consciousness
  • Heart attack
  • Feeling ill
  • Loss of coordination
  • Headaches
  • Nausea
  • Vomiting
  • Seizures
  • Brain damage
  • Anemia
  • Nerve damage
  • Paralysis
  • Vitamin B12 deficiency
  • Nitrous oxide dependency
  • Even death

• Social Media Influence: TikTok and other platforms facilitate exposure to nitrous oxide misuse, despite attempts to restrict such content.

Galaxy Gas Response:

• The company acknowledges concerns about nitrous oxide misuse.
• They emphasize that their products are intended for culinary use only.
• They have paused sales of whipped cream chargers.
• They encourage responsible use and direct users to the Crisis Lifeline for assistance.

Parental Guidance:

• Open and ongoing conversations about substance misuse are crucial.
• Ask questions rather than lecturing to encourage open communication.
• Address social media influences and the dangers of nitrous oxide.

Note: The article highlights the importance of early and open communication between parents and children regarding substance abuse.

https://www.cnn.com/2024/09/20/health/galaxy-gas-trend-nitrous-oxide-risks-wellness